Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment
Garofalo, M., Saari, H., Somersalo, P., Crescenti, D., Kuryk, L., Aksela, L., Capasso, C., Madetoja, M., Koskinen, K., Oksanen, T., Mäkitie, A., Jalasvuori, M., Cerullo, V., Ciana, P., & Yliperttula, M. (2018). Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. Journal of Controlled Release, 283, 223-234. https://doi.org/10.1016/j.jconrel.2018.05.015
Published inJournal of Controlled Release
© 2018 The Authors. Published by Elsevier B.V.
Standard of care for cancer is commonly a combination of surgery with radiotherapy or chemoradiotherapy. However, in some advanced cancer patients this approach might still remaininefficient and may cause many side effects, including severe complications and even death. Oncolytic viruses exhibit different anti-cancer mechanisms compared with conventional therapies, allowing the possibility for improved effect in cancer therapy. Chemotherapeutics combined with oncolytic viruses exhibit stronger cytotoxic responses and oncolysis. Here, we have investigated the systemic delivery of the oncolytic adenovirus and paclitaxel encapsulated in extracellular vesicles (EV) formulation that, in vitro, significantly increased the transduction ratio and the infectious titer when compared with the virus and paclitaxel alone. We demonstrated that the obtained EV formulation reduced the in vivo tumor growth in animal xenograft model of human lung cancer. Indeed, we found that combined treatment of oncolytic adenovirus and paclitaxel encapsulated in EV has enhanced anticancer effects both in vitro and in vivo in lung cancer models. Transcriptomic comparison carried out on the explanted xenografts from the different treatment groups revealed that only 5.3% of the differentially expressed genes were overlapping indicating that a de novo genetic program is triggered by the presence of the encapsulated paclitaxel: this novel genetic program might be responsible of the observed enhanced antitumor effect. Our work provides a promising approach combining anticancer drugs and viral therapies by intravenous EV delivery as a strategy for the lung cancer treatment. ...
ISSN Search the Publication Forum0168-3659
Publication in research information system
MetadataShow full item record
Showing items with similar title or keywords.
Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery Saari, Heikki; Turunen, Tiia; Lõhmus, Andres; Turunen, Mikko; Jalasvuori, Matti; Butcher, Sarah J.; Ylä-Herttuala, Seppo; Viitala, Tapani; Cerullo, Vincenzo; Siljander, Pia R. M.; Yliperttula, Marjo (Taylor & Francis, 2020)Extracellular vesicles (EVs) have been showcased as auspicious candidates for delivering therapeutic cargo, including oncolytic viruses for cancer treatment. Delivery of oncolytic viruses in EVs could provide considerable ...
The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer Saarenheimo, Jatta; Eigeliene, Natalja; Andersen, Heidi; Tiirola, Marja; Jekunen, Antti (Frontiers Media SA, 2019)Targeted therapies have allowed for an individualized treatment approach in non-small-cell lung cancer (NSCLC). The initial therapeutic decisions and success of targeted therapy depend on genetic identification of personal ...
Melanoma-derived hyaluronan-coated extracellular vesicles mediate pro-tumorigenic phenotype in macrophages Korkiamäki, Riku (2022)Melanooma- ja immuunisolujen välinen vuorovaikutus mahdollistaa melanooman kehittymisen pahanlaatuiseksi, sekä metastaasin. Syöpäsoluista peräisin olevat solunulkoiset vesikkelit (extracellular vesicle, EV) pystyvät ...
Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments Hulmi, Juha J.; Nissinen, Tuuli A.; Penna, Fabio; Bonetto, Andrea (MDPI, 2021)Muscle wasting, i.e., cachexia, frequently occurs in cancer and associates with poor prognosis and increased morbidity and mortality. Anticancer treatments have also been shown to contribute to sustainment or exacerbation ...
Musculoskeletal Responses to Exercise plus Nutrition in Men with Prostate Cancer on Androgen Deprivation : A 12-month RCT Via, Jack Dalla; Owen, Patrick J.; Daly, Robin M.; Mundell, Niamh L.; Livingston, Patricia M.; Rantalainen, Timo; Foulkes, Stephen J.; Millar, Jeremy L.; Murphy, Declan G.; Fraser, Steve F. (Lippincott Williams & Wilkins, 2021)Purpose Androgen deprivation therapy (ADT) for prostate cancer (PCa) has multiple adverse effects on musculoskeletal health. This 12-month randomised controlled trial aimed to assess the effects of multi-component exercise ...